The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 6, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q1 FY2022, filed May 6, 2022
The sections below describe the company as of the FY2021 annual report.
Develops targeted drug candidates for rare cancers, with momelotinib in development for people with myelofibrosis.
10-K for FY2021, filed Mar 10, 2022
The company receives upfront license fees under a collaboration agreement with Carna Biosciences.
10-K for FY2021, filed Mar 10, 2022Collaboration revenue consists of upfront license fees recognized under a collaboration agreement with Carna Biosciences, Inc.View ↗
$300K
10-K for FY2021, filed Mar 10, 2022
$300K ↗The company planned to market momelotinib directly to hematologists and oncologists in North America, while exploring partners for commercialization in certain global regions.
No. It lost $80.9M in FY2020.
10-Q for Q1 FY2022, filed May 6, 2022
−$27.9MView ↗
8-K, filed Jul 1, 2022
As described in the Introductory Note, which is incorporated herein by reference in this Item 2.01, on July 1, 2022, pursuant to the terms…View ↗
8-K, filed Apr 13, 2022
On April 12, 2022, Sierra Oncology, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with…View ↗
A new licensed drug candidate
The newer report adds a licensed cancer drug candidate to the portfolio; the earlier report discussed momelotinib and a checkpoint kinase inhibitor.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Mar 10, 2022We are also advancing SRA737, our potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1).…View ↗
In August 2021, we entered into an agreement with AstraZeneca AB (AstraZeneca) to acquire an exclusive global license for SRA515 (formerly…View ↗
Momelotinib advances toward filing
The earlier report anticipated another study to support momelotinib registration; the latest says its pivotal trial produced positive results and that Sierra planned an FDA application.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Mar 10, 2022We are advancing discussions with regulators to determine the registration path for momelotinib and expect to report next steps in the…View ↗
Competes with Incyte, Novartis, Celgene, Bristol Meyers Squibb, CTI Biopharma, Morphosys, AbbVie, Kartos, Geron, Zelgen Biopharmaceuticals, Plexxicon, Zenith Epigenetics, Esperas Pharma, and Acrivon Therapeutics
10-K for FY2021, filed Mar 10, 2022To our knowledge, there are currently three approved myelofibrosis drugs that specifically rely on JAK inhibition, ruxolitinib, marketed by…View ↗
Loading...
